Organization (Industry)
Servier (Spain)
ClinicalTrials.gov lists Servier (Spain) as lead sponsor of 12 trials. It has 26 active development programs and 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 4 in 2026 and about 5 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Servier (Spain): 12 lead-sponsored trials and 7 legal-entity registrations.
Disease areas (71)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 |
| Colorectal Neoplasms | 5 |
| Heart Failure | 5 |
| Hypertension | 5 |
| Leukemia, Myeloid, Acute | 5 |
Showing 5 of 71 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 6 |
| 2024 | 4 |
| 2023 | 9 |
| 2022 | 4 |
| 2021 | 7 |
| 2020 | 3 |
| 2019 | 3 |
| 2018 | 5 |
| 2017 | 5 |
Showing 10 of 19 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (26)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Coversyl 5mg tablet | Hypertension | Phase 3 | 1 |
| Norvasc 5mg tablet | Hypertension | Phase 3 | 1 |
| Norvasc 5mg tablet | Essential Hypertension | Phase 3 | 1 |
| Coversyl 5mg tablet | Essential Hypertension | Phase 3 | 1 |
| Concor 5mg tablet | Essential Hypertension | Phase 3 | 1 |
Showing 5 of 26 active programs.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Gliclazide MR and Insulin Glargine Injection | 1 |
| Biosynthetic Human Insulin Injection | 1 |
| Vorasidenib | 3 |
| Ivosidenib | 1 |
| Posaconazole | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 60% hit target (n=5) | 2 of 4 on time (n=4) |
Journals published in (83)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Critical care medicine | 9 |
| The New England journal of medicine | 7 |
| BMC cancer | 5 |
| European journal of cancer (Oxford, England : 1990) | 5 |
| European heart journal | 4 |
Showing 5 of 83 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 364 | 38 | 2025-11-25 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 4 | 2019-02-21 |
Organization relationships (43)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| GeNeuro SA | Co sponsors trial with | 2 |
| Unicancer | Co sponsors trial with | 2 |
| Nova Laboratories | Co sponsors trial with | 1 |
| Montreal Heart Institute | Co sponsors trial with | 1 |
| The Christie NHS Foundation Trust | Co sponsors trial with | 1 |
Showing 5 of 43 relationships.
Latest dated events (438)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-25 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 438 events.
Biomarker capability evidence (252)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Primary endpoint in a Phase 3 trial |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 252 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.